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Abstract: During the past decades Neural Stem Cells have been considered as an alternative source of cells to replace  
lost neurons and NSC transplantation has been indicated as a promising treatment for neurodegenerative disorders. Never-
theless, the current understanding of NSC biology suggests that, far from being mere spare parts for cell replacement 
therapies, NSCs could play a key role in the pharmacology of neuroprotection and become protagonists of innovative 
treatments for neurodegenerative diseases. Here, we review this new emerging concept of NSC biology. 
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INTRODUCTION 
  Although very different from one another, neurodegen-
erative diseases share common mechanisms, which lead to 
the dysfunction and loss of specific subsets of neurons. The 
general idea is that regardless of the pathogenic mechanism, 
neuronal death is induced by molecular cascades that may be 
common to multiple disorders. For instance, a characteristic 
feature recurring among many neurodegenerative diseases is 
the aggregation and misfolding of particular proteins. The 
affected proteins may differ in different diseases, but the way 
the neurons respond to overwhelming aggregates may con-
verge towards a limited range of cell death pathways. 
  Oxidative stress, inflammation, mitochondrial dysfunc-
tion and defects of axonal transport are among the mecha-
nisms that determine cell degeneration in most neurodegen-
erative disorders. Such commonalities among neurodegen-
erative diseases are particularly appealing, not only because 
they may unravel some general principles governing the bi-
ology of neuronal death, but also because they may allow the 
development of efficient therapeutic approaches for different 
pathological conditions. 
  At present, the available treatments for neurodegenera-
tive diseases are inadequate. They are generally designed to 
counteract symptoms, but they are ineffective in reversing 
the progression of the disease. In this scenario, the possibility 
to increase neuronal survival by interfering with cell death 
processes emerges as a promising strategy to treat different 
neurodegenerative disorders. Once identified and tested for 
their efficacy, neuroprotection procedures might be applied 
either in patients with incipient clinical signs or, as a preven-
tive approach, in individuals that have high risk of develop-
ing the disease in the future. 
*Address correspondence to this author at the Unit of Neuromuscular and 
Neurodegenerative diseases, Children’s Hospital and Research Institute 
“Bambino Gesù”, P.za S. Onofrio, 4, 00165 Rome, Italy: 
Tel: +39-06-68592102; Fax: +39-06-68592024; 
E-mail: barbara.carletti@opbg.net 
  From a biological standpoint a neurocytoprotective effect 
could be achieved through several different ways, such as 
antagonizing the cytotoxic process triggered by the patho-
genic event (e.g. oppose oxidative stress or inflammation-
related processes), or reinforcing endogenous protective sys-
tems (e.g. production of neurotrophic factors, antioxidant 
substances, etc.). 
  To date, the strategies applied to discover effective neu-
roprotective agents have been focused on single pathways 
and only achieved partial results, thus suggesting that the 
concept of neuroprotective treatment should be revised. In-
deed, multiple factors contribute to degenerative processes 
and, therefore, it would be better to consider either multiple 
treatments targeting different cell death cascades, or single 
agents that moderate multiple cell death pathways. In the last 
few years a novel therapeutic opportunity emerged from 
stem cell biology. A series of neural transplantation studies 
highlighted unexpected neuroprotective actions exerted by 
transplanted neural stem cells on dysfunctional host neurons. 
These neuroprotective properties of NSCs appear as the ex-
pression of an interesting developmental program. The study 
of the mechanisms involved in this program and the potential 
use of exogenus NSCs as therapeutic “tools” are indubitably 
very promising and open a new way for future neuroprotec-
tive therapy. Here, we will describe this novel application of 
NSCs for the treatment of neurodegenerative diseases and 
discuss some of the related mechanisms. 
STEM CELLS: EVIDENCE FOR NEUROPROTEC-
TION 
  Several studies have shown that undifferentiated NSCs 
might achieve functional effects in animal models of neuro-
logical disorders following transplantation [1], but a most 
interesting aspect of these reports is that functional im-
provement results from induced self-repair and neuroprotec-
tive effects rather than cell replacement. 
  The notion that NSCs are able to rescue dysfunctional 
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with Parkinson’s disease [2] and spinal cord injury [3]. 
Ourednik and colleagues [2] showed that transplantation of 
NSCs is able to preserve the function of degenerating DA 
neurons following systemic injection of MPTP in the mouse. 
After drug intoxication, the animals underwent unilateral 
implantation of NSCs, which rescued the expression of tyro-
sine hydroxylase and dopamine transporter in the ispilateral 
host DA neurons. In the work by Teng and colleagues [3], a 
similar neuroprotective effect was observed by implanting a 
polymer scaffold seeded with NSCs in a model of traumatic 
spinal cord injury. Animals implanted with scaffold contain-
ing NSCs in the emisectioned spinal cord showed long-term 
improvement of motor function that could be related to re-
duction of secondary degeneration. The functional recovery 
was exerted by the scaffold itself that hampered the forma-
tion of glial scar, but also by the donor NSCs that antago-
nized excitotoxic mechanisms. This effect preserved neurons 
and oligodendrocytes from secondary degeneration and en-
hanced regenerative processes.  
  Following these pioneer works, several studies reported 
neuronal protection as the therapeutic target of NSCs trans-
plantation, and suggested that this property of NSCs could be 
applied to a wide range of neurodegenerative disorders. 
Hence, a neuroprotective action mediated by NSCs has been 
reported in models of multiple sclerosis [4], amyotrophic 
lateral sclerosis [5], stroke [6], Purkinje cell death [7] and 
retinal degeneration [8]. In a mouse form of chronic inflam-
mation, the R-EAE, which mimics aspects of human multi-
ple sclerosis, it was shown that grafted NSCs promote an 
immune-like response that result in a long-lasting neuropro-
tection [4]. NSCs derived from the adult telencephalic sub-
ventricular zone, and intravenously injected in treated mice, 
were recruited around inflamed blood vessel of the deep 
CNS parenchyma where they induced the programmed death 
of infiltrating T cells. This mechanism reduced the extent of 
the neurodegeneration caused by the repeated inflammatory 
episodes of the R-EAE. A similar result was obtained with 
human embryoid body derived cells in a virus induced motor 
neuron disease [9]. EBD cells transplanted into the lumbar 
cerebrospinal fluid migrated into the damaged tissue, proba-
bly responding to environmental attractive cues, and reduced 
motor neurons death, thus promoting functional recovery. 
The general emerging principle is that grafted NSCs act on 
the microenvironment around dying neurons and create con-
ditions that favour their survival. In an elegant study, Clem-
ent and collegues [5] confirmed this idea of neuroprotection 
creating a chimeric model of ALS. They generated mice that 
have both cells with a superoxide dismutase-1 mutation and 
wild type cells and demonstrated that within the spinal cord 
motor neurons carrying the mutation were protected by the 
surrounding wild type cells, presumably astrocyte progeni-
tors. 
  NSCs-mediated host cell rescue and functional recovery 
was also shown in nervous (nr) mutant mice [10], in which a 
subset of Purkinje cells degenerate at the end of develop-
ment. NSC transplantation into the cerebellum of newborn 
mutant mice prevented the loss of host PCs [7]. Similarly, 
subretinal injection of NSCs in a rat model of retinitis   
pigmentosa and secondary photoreceptor degeneration   
preserved retinal activity and function [8]. 
  The molecular mechanisms responsible for the NSC neu-
roprotective action are not fully understood, but likely reside 
in the NSC ability to produce a wide repertoire of neuropro-
tective substances and trophic factors. NSCs constitutively 
produce and secrete neurotrophic factors both in vitro and in
vivo and maintain this property once grafted into the diseased 
CNS [11]. Thus, the NSC therapeutic effect showed in a sig-
nificant number of different cases could be attributable to the 
release of specific soluble factors. Grafts of human HB1.F3 
NSCs (a fetal-derived stem cell line) attenuate parkinsonian 
motor symptoms in 6-hydroxydopamine-lesioned rats, and 
this effect is mainly attributable to the secretion of human 
recombinant SCF [12]. Similarly, EBD cells protect motor 
neurons from degeneration in rats paralyzed after infection 
with neuroadapted Sindbis virus, likely through the produc-
tion of diffusible growth factors TGF-  and BDNF [9]. Fi-
nally, transplanted NSCs (mouse clone C17.2) support the 
growth of motor and sensory axons in the injured spinal cord 
by releasing BDNF, NGF and GDNF [11]. The ability to 
release factors that promote a significant recovery of func-
tion in damaged neural tissue seems also common to some 
other stem cell types, such as for example mesenchymal 
stem cells [for reviews see 13 and 14]. 
  Studies on ischemic stroke revealed that transplanted 
neural progenitor cells exert a therapeutic neuroprotection by 
stimulating anti-inflammatory, glial scar inhibitory and anti-
apoptotic mechanisms. A significant reduction of mRNA 
levels of pro-inflammatory and apoptotic mediators was reg-
istered in the lesioned area after colonization by NPCs and, 
in particular, a down-regulation in the expression of the cy-
tokines TNF- and IFN-  has been suggested to account for 
the increased neuronal survival in the ischemia affected re-
gions of transplanted mice [15]. Furthermore, a direct protec-
tion from apoptotic cell death via caspase activation has been 
for example demonstrated for NGF and BDNF providing 
evidence for a survival promoting mechanism exerted by 
NSC growth factors secretion [16]. Nevertheless, the produc-
tion of diffusible factors might be not the only mechanism 
involved in NSC rescue of imperilled endogenous neurons. 
Recent studies showed that a pivotal role in the dynamic of 
neuroprotection is played by the direct contact between 
NSCs and host neurons via the formation of gap junctions; 
this NSC coupling could not only deliver protective factors, 
but might be also implied to remove toxic molecules, for 
example interacting with reactive glial cells [17].  
NEUROPROTECTIVE PHENOTYPE OF THE “STEM 
CELL” STATE 
  The studies mentioned above have shed a new light on 
the ways stem cells promote neuronal recovery by protecting 
damaged neurons from degenerative mechanisms. Such neu-
roprotective capabilities of NSCs intervene at multiple lev-
els, so that their beneficial effects can be obtained in differ-
ent pathologic conditions. Furthermore, these properties ap-
pear to be active regardless of the NSC species, their source 
or the methods of expansion and propagation [18]. How do 
NSCs exert therapeutic effects in such different conditions? 
Which properties are responsible for these effects? The evi-
dence provided by the available literature in the field clearly 
indicates that the rescue of damaged host neurons is due to 
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state. Following transplantation only a minority of the donor 
NSCs differentiate in mature neurons. Such a restricted frac-
tion of differentiated elements, even if they succeed in inte-
grating into the host circuitries, cannot account for the sig-
nificant therapeutic effects that are frequently observed in 
these conditions. Indeed, the grafts usually contain a pool of 
undifferentiated nestin-positive cells that might be the actual 
effectors of long-lasting beneficial effects on the pathologi-
cal processes [3, 2, 11]. 
  Evan Snyder and colleagues proposed that the neuropro-
tective properties of NSCs could be an aspect of their fun-
damental biology [19]. The “stem cell” state could constitu-
tively express an intrinsic developmental program, which 
may involve an enhanced resistance to environmental stress. 
Indeed, these studies highlight the improved “vigilance” of 
NSCs with respect of endogenous neurons [20]. Hence, to 
realize their therapeutic effect NSCs have to be strongly re-
sistant to the hostile environment of the diseased CNS. This 
is particularly evident when NSCs are transplanted in a toxic 
milieu, such as that of CNS tissue affected by a metabolic 
disorder. NSCs grafted in a mouse model of Krabbe leu-
kodistrophy, characterized by accumulation of the toxic gly-
colipid psichosine, were able to resist to the toxic microenvi-
ronment and made cell replacement possible in a milieu that 
would be otherwise prohibitive for donor cells [21]. How-
ever, the most important outcome of this protective action of 
NSCs is that they are able to provide the neighbouring ma-
ture neurons with the ability to cope with the damage-
perturbation caused by the pathology. For instance, the work 
of Lu and collegues [11] reveals an internal cross-talk among 
the NSC-derived cell population, in which immature cells 
provide trophic support to their daughter cells committed to 
become mature neurons. In this scenario, the adjacent host 
neurons would draw indirect benefit from such NSC-derived 
trophic support. It has been reported that within a NSC clone 
non-neuronal cells produce growth factors, such as GDNF, 
whereas only their neuronal progeny expresses the cognate 
receptor. This phenomenon indicates that stem cells are en-
dowed with particular properties aimed at providing support 
to newborn neurons. This system appears as a sort of mother’s 
care-taking mechanism, in which undifferentiated stem cells 
protect their descendants that have engaged in phenotype 
acquisition, but still require external support to complete their 
maturation and meaningful integration in the neural tissue. 
THE OXIDATIVE STRESS EXAMPLE 
  In this last section of the review we will discuss the neu-
roprotective properties of NSCs considering a particular type 
of cell damage, involved in many neurodegenerative dis-
eases, i.e. oxidative stress. Oxidative stress is caused by an 
imbalance between the production of reactive oxygen species 
and the cellular antioxidant defence, which is usually able to 
detoxify the reactive intermediates and repair the resulting 
damage. Evidence has been accumulating that oxidative 
stress is one of the most common molecular mechanisms 
responsible for the pathogenesis and progression of several 
neurodegenerative diseases. Mitochondrial dysfunction   
and oxidative damage to tissue have been described in Park-
inson’s disease [22-25], Huntinghton’s disease [23, 24], 
Amyotrophic lateral sclerosis [23, 24, 26], Friedreich’s 
ataxia [27-31], Hereditary spastic paraplegia [23, 24, 26] and 
Alzheimer's disease [23, 24, 33]. Therefore, we will first ask 
whether the above described phenomena of stem cell-
mediated neuroprotection can also apply to the case of oxida-
tive stress and, consequently, whether stem cells can be ex-
ploited to counteract this type of neuronal damage. 
  It has been demonstrated that NSCs and their postmitotic 
progeny differ in their redox state [34]. The “stem” cell 
phenotype, because of its self-renewal capacity, is associated 
with a more reduced intracellular environment compared to 
postmitotic neurons. This phenomenon results from a precise 
mechanism, in which the redox state of a stem/progenitor 
cell emerges as a biochemical regulator between self-renewal 
and differentiation. Recently, Madhavan and colleagues [20] 
postulated that the cellular redox condition of NSCs and their 
differentiated progeny also change the ability to defend 
themselves against oxidative stress. These authors demon-
strated that NSCs have lower content of intracellular ROS 
and higher basal levels of several antioxidant molecules, so 
that they are more resistant to oxidative insult than postmi-
totic neurons. NSCs are not only better equipped against 
oxidative stress, but are also able to react more efficiently 
against this dangerous insult by increasing the synthesis of 
antioxidant proteins. Together, these findings indicate that 
stem cell “vigilance” is active and potentially beneficial in 
the occurrence of oxidative stress. But, are NSCs able to 
transmit this increased “vigilance” towards oxidative stress 
also to neighbouring mature neurons? Could be this specific 
antioxidant competence used for a therapeutic purpose in 
neurodegenerative diseases? Indeed, Madhavan and col-
leagues [35] showed that NSCs exert an antioxidant neuro-
protective mechanisms towards the surrounding neurons. 
These authors applied the oxidant drug 3-NP to the neuronal 
microenvironment and demonstrated the protective effect 
exerted by NSCs either co-cultured with primary neurons in
vitro or grafted to the striatum in vivo. These experiments 
showed that NSCs promote an effective antioxidant response 
in the surrounding neuronal cells that usually would not re-
sist to the oxidative insult. The effect involves the release of 
growth factors that directly modulate the activity of antioxi-
dant defence mechanisms. Specifically, secretion of CNTF 
and VEGF correlates with the upregulation of SOD2 both in 
NSCs themselves and in the surrounding cells. A similar 
antioxidant modulator activity has been demonstrated also 
for MSCs [36]. These results lead many authors to envision a 
NSC process in which the secretion of growth factors or neu-
roprotective molecules is adapted to the pathologic environ-
ment to promote survival of affected neurons. In fact, the 
behaviour of NSCs grafted into a diseased nervous system 
seems regulated by a series of graft-host interactions, which 
lead NSCs not only to adjust their migration and distribution, 
but also to regulate the secretion of trophic factors to the 
requirement of the recipient tissue. 
  The cross-talk between NSCs and dysfunctional neurons 
may offer the opportunity to intervene with new treatments 
that favour this interaction. For example, it has been demon-
strated that the increased expression of the adhesion mole-
cule L1 in MPTP lesioned mice enhance the benefits derived 
from NSCs grafts. L1 act in the nervous system during de-
velopmentt and its de novo expression in an adult dysfunc-
tional nervous system may promote those cross-talk mecha-316    Current Neuropharmacology, 2011, Vol. 9, No. 2 Carletti et al. 
nisms normally present during development between NSCs 
and newborn neurons [37]. 
CONCLUDING REMARKS 
  The articles reviewed here highlight a new concept   
of stem cell “restorative biology”. Part of the intrinsic devel-
opmental program of stem cells seems to constitutively   
activate protective and reparative processes in response to 
specific environmental demands. This neuroprotective stem 
cell property is mostly mediated through the release of   
specific trophic factors that modulate the survival capabili-
ties of surrounding neurons. Such a notion may well open 
new perspectives for the treatment of numerous degenerative 
conditions. 
ABBREVIATIONS  
NSCs =  Neural  Stem  Cells 
(MPTP =  1-methyl-4-phenyl-1,2,3,6  tetrahydropyridine   
ALS  =  Amyotrophic lateral sclerosis 
CNS =  Central  nervous  system 
R-EAE  =  Relapsing remitting experimental autoimmune 
encephalomyelitis 
EBD  =  Embryoid body derived 
PCs =  Purkinje  cells 
SCF =  Stem  cell  factor 
BDNF  =  Brain derived neurotrophic factor 
NGF  =  Nerve growth factor 
GDNF  =  Glial derived neurotrophic factor 
MSCs =  Mesenchymal  stem  cells 
NPCs  =  Neural progenitor cells 
TNF-   =  Tumor necrosis factor  
IFN-  =  Interferon-gamma 
ROS  =  Reactive oxygen species 
3NP =  3-nitropropionic  acid 
CNTF  =  Ciliary neurotrophic factor 
VEGF  =  Vascular endothelial growth factor 
SOD2 =  Superoxide  dismutase-2 
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